Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro

Journal of Infectious Diseases

Volumn 191, Issue 3, 2005, Pages 396-399

  Hartline, Caroll B ^a   Gustin, Kortney M ^a   Wan, William B ^b   Ciesla, Stephanie L ^b   Beadle, James R ^b   Hostetler, Karl Y ^b   Kern, Earl R ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACYCLIC NUCLEOSIDE; CIDOFOVIR; ESTER DERIVATIVE; ETHER LIPID; PHOSPHONIC ACID DERIVATIVE; PRODRUG;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SEROTYPE; TISSUE CULTURE CELL; VIRUS REPLICATION; VIRUS STRAIN;

ADENINE; ADENOVIRUSES, HUMAN; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOSINE; ESTERS; ETHER, ETHYL; HUMANS; LIPIDS; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; PHOSPHONIC ACIDS; PRODRUGS; VIRUS REPLICATION;

EID: 12344281761     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/426831     Document Type: Article

References (16)

1. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir Res 1987; 8:261-72.
2. De Clercq E, Holý A, Rosenberg L, Sakuma T, Balzarini J, Maudgal PC. A novel broad-spectrum anti-DNA virus agent. Nature 1986; 323: 464-7.
3. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 2001; 14:382-97.
4. Baba M, Mori S, Shigeta S, de Clercq E. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2′-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother 1987; 31:337-9.
5. De Oliveira C, Stevenson D, LaBree L, McDonnell P, Trousdale M. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res 1996; 31:165-72.
6. Gordon Y, Romanowski E, Araullo-Cruz T, et al. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res 1991; 16:11-6.
7. Gordon Y, Romanowski E, Araullo-Cruz T, de Clercq E. Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model. Cornea 1992; 11:529-33.
8. Romanowski E, Gordon Y. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 2000; 41:460-3.
9. Hillenkamp J, Reinhard T, Ross R, et al. The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 2002; 109:845-50.
10. Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 2001; 27:621-6.
11. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481-6.
12. Beadle JR, Hartline C, Aldern K, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002; 46:2381-6.
13. Keith KA, Wan WB, Ciesla SL, Beadle JR, Hosteller KY, Kern ER. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents Chemother 2004; 48:1869-71.
14. Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002; 46:991-5.
15. Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hosteller KY, Kern ER. Oral treatment of cowpox and vaccinia virus infection in mice with elher lipid eslers of cidofovir. Antimicrob Agents Chemother 2004; 48:404-12.
16. Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, Hosteller KY. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother (in press).